Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells

Purpose: Rational targeted therapies are needed for treatment of ovarian cancers. Signaling kinases, Src and MAPK, are activated in high grade serous ovarian cancer (HGSOC). Here, we tested the frequency of activation of both kinases in HGSOC and the therapeutic potential of dual kinase inhibition. Experimental Design: MEK and Src activation was assayed in primary HGSOC from The Cancer Genome Atlas (TGGA). Effects of dual kinase inhibition were assayed on cell-cycle, apoptosis, gene and proteomic analysis, cancer stem cells and xenografts. Results: Both Src and MAPK are co-activated in 31% of HGSOC, and this associates with worse overall survival on multivariate analysis. Frequent dual kinase activation in HGSOC led us to assay the efficacy of combined Src and MEK inhibition. Treatment of established lines and primary ovarian cancer cultures with Src and MEK inhibitors, saracatinib and selumetinib, respectively, showed target kinase inhibition and synergistic induction of apoptosis and cell cycle arrest in vitro and tumor inhibition in xenografts. Gene expression and proteomic analysis confirmed cell-cycle inhibition and autophagy. Dual therapy also potently inhibited tumor-initiating cells. Src and MAPK were both activated in tumor-initiating populations. Combination treatment followed by drug washout, decreased sphere formation and ALDH1+cells. In vivo, tumors dissociated after dual therapy showed a marked decrease in ALDH1 staining, sphere formation and loss of tumor-initiating cells upon serial xenografting. Conclusions: Selumetinib added to saracatinib overcomes EGFR/HER2/ERBB2-mediated bypass activation of MEK/MAPK observed with saracatinib alone and targets tumor-initiating OVCA populations, supporting further evaluation of combined Src-MEK inhibition in clinical trials.

https://ift.tt/2Kx9LVK